There are two distinct immunological problems in malignant disease. First, there is the effect that malignant disease may have on the normal immunity mechanisms, and this has been studied extensively in man. Secondly, there is the possibility of an immune reaction by the host directed against his own tumour, which in turn leads to the question of whether the behaviour of malignant disease can be modified by immunological procedures. Because of the difficulties of research into this problem in man, most of the experimental work has been done in animals, as already discussed by Professor Alexander.
The Effect ofMalignant Disease on Immunological Reactions to Foreign Antigens It is worth considering the effect of malignant disease on the normal immune mechanisms first, as it has been suggested that impairment of the immune system might predispose to the development of malignant disease. It is necessary to consider problems of antibody formation and cellular immunity separately.
Circulating antibodies: Since antibodies are produced by cells of the lymphocyte-plasma cell series, it is hardly surprising that it is in the primary malignant diseases of these cells that antibody formation is most severely affected. The production of circulating antibody following immunization with an antigen the patient has not encountered before (the primary response) is impaired in some late cases of carcinoma, and early in patients with primary malignant diseases of lymphoreticular tissue (reticuloses), the immunological deficit being most marked in the malignant diseases of lymphocytes and plasma cells (chronic lymphocytic leuk&emia and myelomatosis). When an antigen that the patient has experienced before is used to test the secondary response, antibody formation is found to be grossly impaired in chronic lymphocytic leukemia and myelomatosis; while the response in the other reticuloses, and even late cases of carcinoma, is usually normal (Greenwood et al. 1958 , Fairley & Akers 1962 , Lytton et al. 1964 ).
Cellular immunity: This has been studied by measuring delayed hypersensitivity reactions, homograft rejection, and by using the lymphocyte transfer test of Brent & Medawar (1964) .
In patients with reticuloses there is frequently impairment of the delayed hypersensitivity reaction, particularly in Hodgkin's disease (Fairley & Matthias 1960 , Aisenberg 1966 . A similar suppression may also occur in late cases of carcinoma (Lamb et al. 1962 ). The work of Hughes & Mackay (1965) suggests that patients with malignant disease and anergy to tuberculin may have a worse prognosis than those who respond to tuberculin, and certainly the impairment of delayed hypersensitivity in both reticuloses and carcinomas is not due to general debility, because patients with debilitating non-neoplastic diseases show normal delayed hypersensitivity responses (Levin et al. 1964 ).
The survival of skin homografts is prolonged in patients who show a marked suppression in the delayed hypersensitivity response, and in the lymphocyte transfer test Robinson & Hochman (1966) found that lymphocytes from normal donors produced greater reactions than lymphocytes from patients with malignant disease. (Martin et al. 1965) , or if there is some degree of histocompatibility between the donor and the recipient, or if the latter is old (Scanlon et al. 1965 ). In view of this, it is clearly dangerous in some circumstances to transplant human malignant tissue into apparently healthy recipients, and is now ethically unjustifiable.
(2) Autografts: the subcutaneous implantation of malignant cells or biopsy material from the patient's own tumour may give rise to 'takes' depending on the experimental conditions. Southam in 1965 found that the number oftumour cells required to produce a successful autograft was related to the ability of the patient to reject a homograft of tumour cells, and this in turn was related to the immunological state of the patient as judged by the tuberculin test, the ability to develop delayed hypersensitivity to DNFB and the macrophage response in inflammatory exudates. The greater the immunological defect, the fewer cells were required to establish a tumour autotransplant. Southam also found with tumour autotransplants that by mixing the tumour cells with the patient's own lymphocytes there was often an inhibition of growth at the site of the injection. This, of course, is very similar to the situation described by Professor Alexander in animals, and strongly supports the idea that in these patients the lymphocytes are reacting against the tumour.
Histological evidence: The natural history of malignant disease is related to the morphology of the tumour. Black et al. (1955 Black et al. ( , 1956 and Black & Speer (1958) showed that the prognosis in carcinoma of the breast and stomach was related to the degree of nuclear differentiation, the amount of lymphoid infiltration in the primary tumour and the presence of sinus histiocytosis in the regional lymph nodes. The greater the degree of differentiation, lymphoid infiltration and sinus histiocytosis, the better the prognosis. Lukes (1964) has shown that a similar situation arises in Hodgkin's disease where lymphocytic depletion is associated with a poor prognosis and widespread disease; lymphocytic and/or histiocytic proliferation is associated with a better prognosis and localized disease.
We have recently been studying the lymphocytes in the peripheral blood of patients with Hodgkin's disease (Crowther & Fairley 1967) and have found that, in new untreated cases, the lymphocyte population is abnormal. There is a higher percentage of large lymphoid cells which are actively synthesizing DNA and some of them contain endoplasmic reticulum. One possible explanation for this is that these lymphocytes are involved in an immunological reaction, and this is supported by the fact that in ordinary infections, and following any immunization procedure, lymphoid cells identical with those found in Hodgkin's disease are present in the peripheral blood.
In view of these findings it might seem surprising that in Hodgkin's disease there should be such gross impairment in cellular immunity, but it may be that most of the lymphocytes are committed to react against Hodgkin's tissue and are, therefore, unable to react against other antigens.
The phenomenon of spontaneous regression and evidencefrom treatment: There are now a number of established cases in which spontaneous regression has occurred (Everson & Cole 1956 , Smithers 1962 , Everson 1964 ; and also Burchenal (1966) has collected 132 cases of acute leukemia who have survived 5 years, some of whom appeared to be cured. It is difficult to know the part played by host defence mechanisms in these cases, but a more dramatic situation has now arisen with the Burkitt African lymphoma. Regressions of tumour masses with freedom from recurrence for up to 5 years have followed the single injection of either methotrexate or cyclophosphamide (Burkitt et al. 1965) . It is extremely unlikely that this treatment could have killed all the malignant cells, and the results suggest that there is a host resistance as well, that could be immunological.
Immunotherapy
It is with the background of this evidence that there may be a reaction, mediated by lymphocytes, by the patient against his own malignant disease, that the problem of immunotherapy in man should be considered. The use of vaccines or antisera will not be considered here as so far these have proved disappointing. Woodruff & Nolan (1963) treated 8 patients with advanced carcinomatosis by injecting spleen cells from another individual after preparatory treatment of the recipient with a cytotoxic drug designed to delay rejection of the foreign cells. All cases showed some slight improvement. These cells had, of course, not been immunologically activated as the donor had not been immunized with tumour cells.
Following the experience with primary rat tumours, already described by Professor Alexander, Nadler & Moore (1966) took pairs of patients with incurable malignant disease. A biopsy of the malignant tissue was taken from each patient and implanted subcutaneously into the other and vice versa. After 10-14 days white cells were collected from the blood of the recipients of the tumour grafts and injected back into the donor. Seven out of 26 patients derived some benefit from this, and 2 patients had complete objective remission, one of which had lasted for two years at the time of publication.
For the first time it now looks as if it may be possible to influence the course of human malignant disease using immune lymphocytes, and there is no doubt that further investigation of the activity of lymphocytes in malignant disease should produce essential information about resistance to tumours in man.
